{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lum SH"],"funding":["Wellcome Trust"],"pagination":["1319-1328"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8864655"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(4)"],"pubmed_abstract":["Hematopoietic cell transplantation (HCT) has become standard-of-care for an increasing number of inborn errors of immunity (IEI). This report is the first to compare transplant outcomes according to T-cell-replete (ie, T-replete) HLA-matched grafts using alemtuzumab (n = 117) and T-cell-depleted (ie, T-depleted) HLA-mismatched grafts using T-cell receptor-αβ (TCRαβ)/CD19 depletion (n = 47) in children with IEI who underwent first HCT between 2014 and 2019. All patients received treosulfan-based conditioning except patients with DNA repair disorders. For T-replete grafts, the stem cell source was marrow in 25 (21%) patients, peripheral blood stem cell (PBSC) in 85 (73%), and cord blood in 7 (6%). TCRαβ/CD19 depletion was performed on PBSCs from 45 haploidentical parental donors and 2 mismat"],"journal":["Blood advances"],"pubmed_title":["T-replete HLA-matched grafts vs T-depleted HLA-mismatched grafts in inborn errors of immunity."],"pmcid":["PMC8864655"],"funding_grant_id":["204721/Z/16/Z"],"pubmed_authors":["Leahy TR","Lum SH","January R","Gennery AR","Williams E","Carruthers K","Owens S","Perez-Heras I","Abinun M","Watson H","Slatter M","Greener S","Payne RP","Hambleton S","Nademi Z","Waugh S","Cant A","Drozdov D","Flood T","Burton-Fanning S"],"additional_accession":[]},"is_claimable":false,"name":"T-replete HLA-matched grafts vs T-depleted HLA-mismatched grafts in inborn errors of immunity.","description":"Hematopoietic cell transplantation (HCT) has become standard-of-care for an increasing number of inborn errors of immunity (IEI). This report is the first to compare transplant outcomes according to T-cell-replete (ie, T-replete) HLA-matched grafts using alemtuzumab (n = 117) and T-cell-depleted (ie, T-depleted) HLA-mismatched grafts using T-cell receptor-αβ (TCRαβ)/CD19 depletion (n = 47) in children with IEI who underwent first HCT between 2014 and 2019. All patients received treosulfan-based conditioning except patients with DNA repair disorders. For T-replete grafts, the stem cell source was marrow in 25 (21%) patients, peripheral blood stem cell (PBSC) in 85 (73%), and cord blood in 7 (6%). TCRαβ/CD19 depletion was performed on PBSCs from 45 haploidentical parental donors and 2 mismat","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2026-05-31T05:00:12.918Z","creation":"2025-08-21T09:50:29.38Z"},"accession":"S-EPMC8864655","cross_references":{"pubmed":["34972212"],"doi":["10.1182/bloodadvances.2020004072"]}}